PARP14 and hepatocellular carcinoma: Particularly, PARP14 can promote glycolysis in different tumor models, such as human hepatocellular carcinoma (HCC), by maintaining reduced PKM2 activity (Iansante et al., 2015); on the other hand, a close relationship between c-myc and AKT has been reported in B lymphomas (Cho et al., 2011) and AML through the NF-κB/HIF-1α axis (Zhu et al., 2022).